Botox® is a medication used to reduce or smooth the appearance of deep wrinkles in various places on the face, particularly around the eyes. At Associated Dermatology and Advanced Laser Clinic, you can benefit from the years of experience Janel Zitzka, LPN has with the treatment of Botox®.
Janel has experience treating person with Botox® for hyperhidrosis (excess sweating) and for blepharospasm which is an uncontrolled twitching of the eyelids.
Janel will discuss this treatment with you more fully including side effects and other important information you should know before undergoing treatment.
BOTOX® Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in patients 18 to 65 years of age.
Associated Dermatology & Advanced Laser Clinic
Joins with Botox to Support Your Lifestyle!
Ask about our scheduling, pricing, and promotion options
Consultations are Always Complimentary
Professional, Prompt… Perfection
- At the Advanced Laser Clinic of Associated Dermatology, Janel will make sure that keeping your relaxed and composed image is never compromised.
- We promise to be there for you when you need us, regardless of the time or day (1).
- We understand your busy schedule, impromptu (and fleeting) free moments and general demands of life, work and family.
- Patients appreciated flexibility of scheduling – Call for an Appointment. We will do our best to work around your schedule to ensure that Botox continues to be a treat for you, rather than a burden.
Call (406) 324-7447 to Set-up Your FREE Consultation with Janel!
(1) Applies to regular business hours, excludes weekends and holidays.
(2) The opinion of Dr. Patrick Bitter, Jr.
* Janel Zitzka, LPN, Certified Laser Technician. Certified Laser Safety Officer, Certified Botox and Juvederm Injector, CAC Level 3
IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
Distant Spread of Toxin Effect: post-marketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have occurred at doses comparable to those used to treat cervical dystonia and at lower doses.
The recommended dosage and frequency of administration for BOTOX® Cosmetic should not be exceeded. Risks resulting from administration at higher dosages are not known.
Lack of Interchangeability Between Botulinum Toxin Products: the potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of BOTOX® Cosmetic cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method.
Spread of Toxin Effect: no definitive, serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines) have been reported.
Hypersensitivity Reactions: serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.
Pre-existing Neuromuscular Disorders: individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of BOTOX® Cosmetic.
Human Albumin: this product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.
Precautions: caution should be used when BOTOX® Cosmetic (onabotulinumtoxinA) treatment is used in patients who have an inflammatory skin problem at the injection site, marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, or the inability to substantially lessen glabellar lines by physically spreading them apart.
Information for Patients: patients should be counseled that if loss of strength, muscle weakness, or impaired vision occur, they should avoid driving a car or engaging in other potentially hazardous activities.
Drug Interactions: co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like nondepolarizing blockers, lincosamides, polymyxins, quinidine, magnesium sulfate, anticholinesterases, succinylcholine chloride) should only be performed with caution as the effect of the toxin may be potentiated.
The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
Pregnancy: administration of BOTOX® Cosmetic is not recommended during pregnancy. There are no adequate and well-controlled studies of BOTOX® Cosmetic in pregnant women.
Nursing Mothers: it is not known whether BOTOX® Cosmetic is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BOTOX® Cosmetic is administered to a nursing womam.
General Adverse Reactions: the most serious adverse events reported after treatment with botulinum toxin include spontaneous reports of death, sometimes associated with anaphylaxis, dysphagia, pneumonia, and/or other significant debility.
There have also been reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease.
The most frequently reported adverse events following injection of BOTOX® Cosmetic include blepharoptosis and nausea.